X
<

These Are Gilead Sciences’ Key Growth Drivers

PART:
1 2 3 4 5 6 7
Part 6
These Are Gilead Sciences’ Key Growth Drivers PART 6 OF 7

How Gilead’s Other Products Performed in 2Q17

Gilead’s portfolio  

Apart from Gilead Sciences’ (GILD) antiviral drugs portfolio, the company also includes drugs in therapeutic areas like cardiovascular, inflammation, oncology, and respiratory in its portfolio.

How Gilead’s Other Products Performed in 2Q17

Interested in GILD? Don't miss the next report.

Receive e-mail alerts for new research on GILD

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart shows revenues for Gilead’s other products over the last few quarters. The other products franchise contributes less than 10% of total revenues. For 2Q17, other products reported revenues of $607 million as compared to revenues of $535 million during 2Q16.

Cardiovascular portfolio

The cardiovascular portfolio includes three drugs: Letairis, Lexiscan, and Ranexa. Letairis is used in the treatment of patients with pulmonary arterial hypertension. The Lexiscan injection is used as a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging. Ranexa is used for the treatment of patients with chronic angina. The drugs Letairis and Ranexa reported revenues of $230 million and $200 million, respectively, during 2Q17.

Inflammation and respiratory portfolio

The inflammation and respiratory portfolio include two drugs, Cayston and Tamiflu. Cayston improves the respiratory symptoms in patients with cystic fibrosis and pseudomonas aeruginosa. Tamiflu, an influenza neuraminidase inhibitor, is used for the treatment of influenza infections.

Oncology portfolio  

Zydelig, an oncology drug from Gilead, is approved for use in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (or CLL), relapsed follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma in patients with at least two prior treatments. Zydelig reported revenues of $35 million during 2Q17, a 15% decline as compared to $41 million in 2Q16.

Others

Other drugs from Gilead Sciences include AmBisome and Macugen. AmBisome reported revenues of $92 million during 2Q17, an 8% growth as compared to $85 million in 2Q16.

To divest the company-specific risks, investors can consider ETFs like the First Trust NYSE Arca Biotechnology ETF (FBT), which holds 3.7% of its total assets in Gilead Sciences. FBT also holds 5.2% in Kite Pharma (KITE), 3.6% in Biogen (BIIB), and 3.9% in Illumina (ILMN).

X

Please select a profession that best describes you: